Home' Australian Pharmacist : Australian Pharmacist June 2016 Contents Australian Pharmacist June 2016 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Formula, method and stability
A formula and method of preparation for
Gabapentin (5%) in Lipoderm is shown in
Figure 3, adapted from Bryson E, Asbill
S, Sweitzer S.6 A Gabapentin (6%) in
Lipoderm formula has been shown to be
stable for 90 days.9 Gabapentin has also
been combined with other analgesics for
topical delivery, which may be beneficial
since different types of pain receptors
are targeted by these various agents,
resulting in greater overall treatment
Gabapentin (5%) in Lipoderm
gabapentin (API) 2.5 g
propylene glycol 3 mL (density is
1. Weigh the required amount of
active pharmaceutical ingredient
(API) and add to a mortar.
2. Use the propylene glycol as a
levigating agent and then add the
Lipoderm base in small quantities
(geometric dilution) until the total
base has been added.
3. Transfer to an appropriate
container and label appropriately.
Ointment paper can be used if
transferring to an ointment tube.
Note: Lipoderm may be replaced with
an appropriate base as required by
Figure 3. Formula and method of preparation
Packaging, storage and labelling
Many packaging options are available
and the choice may be dictated by
patient preference for a particular
type of packaging. Contact your local
supplier for packaging options. It is
important that patients and carers
are counselled on the correct use,
storage and appropriate disposal of the
packaging. The preparation should be
stored out of reach of children and pets.
Compounded products are to be
labelled according to regulatory
and should include
the approved pharmacopoeial name
(where applicable) and the name and
strength of any preservatives used. All
active ingredients and their amounts/
proportions should be included if a
pharmacopoeial formulation is not used.
Ancillary labels should specify storage
conditions, provide an expiry date and
indicate specific usage conditions.
Labels 1, 9, 12 and 23 should be
Include Label K to indicate FOR
EXTERNAL USE ONLY.
This medicine may cause
drowsiness and may
increase the effects of alcohol.
If affected, do not drive a motor
vehicle or operate machinery.
Do noT sTop TAking This
meDicine AbrupTly unless
otherwise advised by your doctor.
This medicine may affect mental
alertness and/or coordination.
if affected, do not drive a motor
vehicle or operate machinery.
This product has been
compounded by the pharmacist.
For eXTernal use only
The pharmacist is responsible for
ensuring the quality of compounded
products and should verify that
products are prepared according to
documented procedures and meet
product specifications before release to
Reviews of processes and procedures
should be conducted regularly in order to
identify areas for improvement, and the
resulting actions should be documented.
In the preparation of compounded
products, the pharmacist is guided by
the PSA Professional Practice Standards,
the prescriber and the needs of the
carer and patient. Patient counselling
and education may be adapted from
consumer medicines information
leaflets (CMIs) available for commercial
Essential information should
Patient advice and counselling
Adverse effects and special precautions
would be as for the oral preparations,
and are outlined in the Australian
Medicines Handbook and APF23.3,4
Common adverse effects include
somnolence, dizziness and ataxia.2,3,4
Immediate medical attention should be
sought if any signs of allergic reactions
develop, for example, rash, fever,
swelling or tenderness under armpits
or on the neck, or difficulty breathing.
Therapeutic Guidelines outline a
number of non-pharmacological
treatments for the management of
chronic pain, including physical, mind-
body and psychological techniques;
SOLUTIONS THROUGH COMPOUNDING
"GABAPENTIN HAS ALSO
BEEN COMBINED WITH OTHER
ANALGESICS FOR TOPICAL
DELIVERY, WHICH MAY BE
BENEFICIAL SINCE DIFFERENT
TYPES OF PAIN RECEPTORS ARE
TARGETED BY THESE VARIOUS
Links Archive Australian Pharmacist May 2016 Australian Pharmacist July 2016 Navigation Previous Page Next Page